Clinical Trials Logo

Atherosclerosis clinical trials

View clinical trials related to Atherosclerosis.

Filter by:

NCT ID: NCT03559309 Not yet recruiting - Clinical trials for Cardiovascular Diseases

Investigating the Effects of Lipid-therapy Intensification With Alirocumab on Endothelial Function, Carotid Arteries, Lipoprotein Particle Subfractions, Inflammation and Post-prandial Lipemia

ALIROCKS
Start date: June 20, 2018
Phase: Phase 4
Study type: Interventional

A prospective, open-label, pilot study with 24 cardiovascular high risk patients (N=24) having insufficient Low density lipoprotein cholesterin (LDL-C) reduction despite standard of care lipid-modifying therapies (LMTs), to evaluate the effects of potent lipid-therapy intensification via the recently approved monoclonal, human anti-PCSK9 antibody Alirocumab on endothelial function, inflammation, lipoprotein particle subfractions, carotid arteries and post-prandial lipemia in clinical routine at the Medical University of Graz.

NCT ID: NCT03542110 Not yet recruiting - Clinical trials for Saphenous Vein Graft Atherosclerosis

The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial

ASAP-SVG
Start date: August 2018
Phase: Phase 4
Study type: Interventional

This is a phase IV, multi-center, double-blind, randomized, placebo- controlled study evaluating the effect of alirocumab on SVG atherosclerotic disease burden, as assessed by IVUS at baseline and following 78 weeks of treatment in subjects with at least one intermediate SVG lesion receiving optimal statin therapy. Subjects will be randomized 1:1 into 2 treatment groups: alirocumab 150 mg subcutaneously every 2 weeks or placebo subcutaneously every 2 weeks.

NCT ID: NCT03538067 Not yet recruiting - Clinical trials for Coronary Artery Disease

Balloon Inflation and Plaque Morphology in Revascularisation (BURST)

BURST
Start date: June 2018
Phase:
Study type: Observational

This study will look at the effects of standardised balloon inflation times, pressure and balloon types and atherosclerotic plaque morphology on the procedural results of percutaneous coronary intervention (PCI).

NCT ID: NCT03530176 Completed - Atherosclerosis Clinical Trials

18F-Sodium Fluoride (18F-NaF) PET-CT Imaging to Identify Vulnerable Plaques in Patients With Diabetes

D-NaF
Start date: January 1, 2015
Phase: N/A
Study type: Interventional

Coronary artery calcification is a sign of heart disease. A nuclear medicine PET-CT test using sodium fluoride (18F-NaF) radioisotope has been shown to help identify growing calcification plaques early on in the disease process. It is known that diabetic patients are at a high risk of developing premature coronary disease; the investigators intend to use this new technology to identify those patients at higher risk of developing coronary artery disease.

NCT ID: NCT03528473 Not yet recruiting - Atherosclerosis Clinical Trials

Adapted Physical Activity (APA) in a Breast Cancer Population.

Start date: June 21, 2018
Phase: N/A
Study type: Interventional

The aim of this study is to investigate the effect of a 6-months program of Adapted Physical Activity (APA) on body composition, insulin resistance and adipokines, oxidative stress and microcirculatory haemodynamics in post-menopausal, physically inactive breast cancer patients in oncological follow-up with or without hormone therapy that had completed adjuvant treatment (radiotherapy and/or chemotherapy). Furthermore, the study will determine the impact of APA on functional capabilities, on self-reported physical activity, quality of life and psychic health.

NCT ID: NCT03526042 Recruiting - Atherosclerosis Clinical Trials

Angiotensin-II Receptor Antibodies Blockade With Losartan in Patients With Lupus Nephritis

Start date: September 10, 2017
Phase: N/A
Study type: Interventional

Antibodies directed against angiotensin-II receptor (AT1-Ab) are agonist antibodies previously studied in human diseases such as preeclampsia, transplantation and scleroderma. They act by binding to the AT1 receptor and their effects can be blocked with the use of angiotensin receptor blockers (ARB). In this randomized open clinical trial the investigators will study the effect of the blockade of AT1-Ab with losartan in carotid intima-media thickness progression in patients with lupus nephritis compared to patients treated with enalapril.

NCT ID: NCT03518437 Recruiting - Clinical trials for Coronary Artery Disease

Coronary Atherosclerosis Disease Early Identification and Risk Stratification by Noninvasive Imaging

Creation
Start date: September 2016
Phase:
Study type: Observational [Patient Registry]

The investigator prospectively enroll 30,000 outpatients who were suspected of coronary artery disease (CAD) and underwent cardiac computed tomography angiography (CTA). The endpoint was major adverse cardiac events (MACE).The investigator aim to evaluate the prognostic value of CTA, risk factors and bio-markers for MACE.

NCT ID: NCT03507777 Recruiting - Clinical trials for Coronary Artery Disease

ILUMIEN IV: OPTIMAL PCI

Start date: March 26, 2018
Phase: N/A
Study type: Interventional

The objective of this clinical investigation is to demonstrate the superiority of an Optical Coherence Tomography (OCT)-guided stent implantation strategy as compared to an angiography-guided stent implantation strategy in achieving larger post-PCI lumen dimensions and improving clinical cardiovascular outcomes in patients with high-risk clinical characteristics and/or with high-risk angiographic lesions.

NCT ID: NCT03507374 Not yet recruiting - Stroke Clinical Trials

PCSK9 Inhibition in Patients With Symptomatic Intracranial Atherosclerosis

Start date: June 2018
Phase: Early Phase 1
Study type: Interventional

This will be a randomized double blind placebo-controlled pilot study using a repeated measures design in which participants with acute ischemic stroke and intracranial atherosclerotic disease are randomized to either drug or placebo.

NCT ID: NCT03504956 Not yet recruiting - Clinical trials for Coronary Atherosclerosis

Coronary Atherosclerosis T1-Weighted Characterization (CATCH)

CATCH
Start date: May 30, 2018
Phase: N/A
Study type: Interventional

This study proposes to develop an MRI technique named Coronary Atherosclerosis T1-weighed Characterization (CATCH) that will improve the quality and reliability of coronary atherosclerosis evaluation, as well as simplify the scanning process and significantly shorten imaging time compared with conventional imaging methods.